

VALEANT PHARMACEUTICALS INTERNATIONAL
Form SC 13G/A
February 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4) *

Valeant Pharmaceuticals International

(Name of Issuer)

Common Stock

(Title of Class of Securities)

448924-10-0

(CUSIP Number)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/X/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1
of 7 Pages

SCHEDULE 13G

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

CUSIP NO. 448924-10-0

Page 2 of 7 Pages

 (1) NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Global Markets Holdings Inc.

 (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /

(b) / /

 (3) SEC USE ONLY

 (4) CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF	(5) SOLE VOTING POWER	0
SHARES		
BENEFICIALLY	(6) SHARED VOTING POWER	4,680,690*
OWNED BY		**
EACH	(7) SOLE DISPOSITIVE POWER	0
REPORTING		
PERSON	(8) SHARED DISPOSITIVE POWER	4,680,690*
WITH:		**

 (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,680,690*
 **

 (10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

 (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.6%*
 **

 (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

 * Assumes conversion/exercise of certain securities held.

** Includes shares for which the reporting person disclaims beneficial ownership. See Item 4(a)

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

SCHEDULE 13G

CUSIP NO. 448924-10-0

Page 3 of 7 Pages

(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Inc.

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /
(b) / /

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF	(5) SOLE VOTING POWER	0
SHARES		

BENEFICIALLY	(6) SHARED VOTING POWER	5,399,644*
OWNED BY		**

EACH	(7) SOLE DISPOSITIVE POWER	0
REPORTING		

PERSON	(8) SHARED DISPOSITIVE POWER	5,399,644*
WITH:		**

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	5,399,644*
	**

(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	6.4%*
	**

(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

-
- * Assumes conversion/exercise of certain securities held.
 - ** Includes shares for which the reporting person disclaims beneficial ownership. See Item 4(a)
 - *** Includes shares held by the other reporting persons.

- Item 1(a). Name of Issuer:
Valeant Pharmaceuticals International
- Item 1(b). Address of Issuer's Principal Executive Offices:
3300 Hyland Avenue
Costa Mesa, California 92626
- Item 2(a). Name of Person Filing:
Citigroup Global Markets Holdings Inc. ("CGM Holdings")
Citigroup Inc. ("Citigroup")
- Item 2(b). Address or Principal Office or, if none, Residence:
The address of the principal office of CGM Holdings is:
388 Greenwich Street
New York, NY 10013
The address of the principal office of Citigroup is:
399 Park Avenue
New York, NY 10043
- Item 2(c). Citizenship or Place of Organization:
CGM Holdings is a New York corporation.
Citigroup is a Delaware corporation.
- Item 2(d). Title of Class of Securities:
Common Stock
- Item 2(e). Cusip Number:
448924-10-0

Page 4
of 7 Pages

- Item 3. If this Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a(n):
- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (see Exhibit 2)
- (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
- (j) Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership. (as of December 31, 2003)

- (a) Amount beneficially owned: See item 9 of cover pages
(Includes shares for which the reporting person disclaims beneficial ownership.)
- (b) Percent of Class: See item 11 of cover pages
- (c) Number of shares as to which the person has:
 - (i) sole power to vote or to direct the vote:
 - (ii) shared power to vote or to direct the vote:
 - (iii) sole power to dispose or to direct the disposition of:
 - (iv) shared power to dispose or to direct the disposition of:

See Items 5-8 of cover pages

Page 5
of 7 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company.

See Exhibit 2 for the identification and classification of the subsidiary that directly beneficially owns the securities reported herein.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Page 6
of 7 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2004

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

By: /s/ Joseph B. Wollard

Name: Joseph B. Wollard
Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Serena D. Moe

Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form SC 13G/A

Name: Serena D. Moe
Title: Assistant Secretary

Page 7
of 7 Pages

EXHIBIT INDEX TO SCHEDULE 13G

EXHIBIT 1

Agreement between CGM Holdings and Citigroup as to joint filing of
Schedule 13G

EXHIBIT 2

Identification and classification of the subsidiary that acquired the
securities reported by parent holding company.